2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
The National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center – Jefferson Health (SKCC) is a nationally recognized center for practice-changing discovery and comprehensive cancer treatment, offering a depth and breadth of experience in all aspects of cancer from the laboratory to the clinic. Our mission is to improve the lives of cancer patients and their families through compassion, innovation, and breakthrough discoveries. For more information, visit sidneykimmelcancercenter.jeffersonhealth.org.
July 31, 2024
Article
Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, detail a health care cost impacts model pertaining to the use of cannabis for therapy-related symptoms
April 26, 2024
Video
Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
April 26, 2024
Video
Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.
April 25, 2024
Video
Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.
April 02, 2024
Article
Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.
March 29, 2024
Article
Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.
March 08, 2024
Article
The burst of translational research leading to PARP inhibitors in prostate cancer, along with imaging and diagnostic advances, has been a monumental evolution for the management of this disease.
February 01, 2024
Video
Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.
January 12, 2024
Video
Maria Hafez, MD, explains how hormone receptor status, risk stratification, & other factors influence clinical decisions in early HER2+ breast cancer.
December 13, 2023
Article
Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.
October 18, 2023
Article
OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, have announced the winners of the 2023 Luminary Award in GI cancers.
October 18, 2023
Article
Kevin Kayvan Zarrabi, MD, MS, FACP, discusses the emergence of triplet therapy of ADT, AR-targeted therapy, and cytotoxic chemotherapy for patients with mHSPC; highlights key trials that have explored and supported the use of these triplets; and expands on the unanswered questions that remain regarding patient selection and chemotherapy eligibility.
June 05, 2023
Video
Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
May 29, 2023
Video
Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.
May 29, 2023
Video
Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.
May 22, 2023
Video
Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.
May 22, 2023
Video
A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.
May 15, 2023
Video
Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.
May 15, 2023
Video
Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.
May 08, 2023
Video
Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.